David Hallal, Scholar Rock CEO, joins 'Fast Money' to talk its recent drug study results that found its drug taken in combination with Zepbound helped prevent muscle loss.

Scholar Rock's Apitegromab excels in Phase 2 trials, aiding muscle preservation with Tirzepatide. Click here to read why I think SRRK stock could be a Buy.

Get the latest Scholar Rock Holding Corporation (SRRK) stock news and headlines to help you in your trading and investing decisions.

Scholar Rock Holding Corp.’s stock soared more than 315% Monday to put it on track for its biggest ever one-day gain, after the clinical-stage biotech company said a late-stage trial of a ...

Scholar Rock receives fast track designation from the FDA for Apitegromab for the treatment of patients with spinal muscular atrophy.

Scholar Rock is a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need.

The market celebrated Scholar Rock's upsized stock offering and plans to advance development of a new obesity treatment. Here's what investors need to know.

Scholar Rock announced that Dr. Srinivas Akkaraju has been appointed to Scholar Rock’s Board of Directors as an independent director.

I analyze Scholar Rock's promising Phase 3 results for SMA drug, but warn of financial challenges and recommend a Hold rating. Read more here.

Scholar Rock's surprising success Apitegromab is an antibody that binds to another protein called myostatin, which normally works to limit muscle growth. It's being tested in the phase 3 Sapphire ...

Scholar Rock, a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy and additional severe and debilitating ...

CAMBRIDGE, Mass., April 30, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in ...